Published in Haematologica on May 05, 2011
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50
Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia (2012) 1.22
Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica (2013) 1.17
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res (2013) 1.15
Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int (2014) 0.98
The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene (2012) 0.93
Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica (2015) 0.91
Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiation. Chromosome Res (2015) 0.82
Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica (2014) 0.82
SNP Array in Hematopoietic Neoplasms: A Review. Microarrays (Basel) (2015) 0.82
Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Leukemia (2013) 0.81
Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes Cancer (2015) 0.80
Uncovering the DNA methylome in chronic lymphocytic leukemia. Epigenetics (2013) 0.80
Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Genet (2014) 0.78
Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. Cancer Genet (2014) 0.78
Genetic Variation Associated with Longer Telomere Length Increases Risk of Chronic Lymphocytic Leukemia. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia? Per Med (2013) 0.78
Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica (2016) 0.78
A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia. Clin Cancer Res (2016) 0.77
Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol (2017) 0.75
Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K). Mol Cytogenet (2016) 0.75
Activation of the NOTCH1 pathway in chronic lymphocytic leukemia. Haematologica (2012) 0.75
State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia. Clin Med Insights Oncol (2012) 0.75
Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. Leukemia (2016) 0.75
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. Chin Med J (Engl) (2017) 0.75
Characteristics of chronic lymphocytic leukemia in Senegal. BMC Hematol (2016) 0.75
Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia. Indian J Hematol Blood Transfus (2016) 0.75
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med (2000) 16.30
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 11.50
A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics (2005) 10.43
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med (1990) 3.21
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood (2006) 2.36
Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood (2008) 2.35
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica (2007) 1.99
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia (2007) 1.97
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia (2008) 1.76
Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res (2008) 1.74
Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer (2008) 1.16
Quantification of normal cell fraction and copy number neutral LOH in clinical lung cancer samples using SNP array data. PLoS One (2009) 1.14
Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn (2008) 1.13
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol (2008) 1.12
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res (2008) 1.11
Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res (2010) 1.10
Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood (1985) 1.08
Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res (2009) 0.94
Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol (1998) 0.90
Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization. Neoplasma (2009) 0.83
Consistency of chromosomal aberrations in chronic B-lymphocytic leukemia. A longitudinal cytogenetic study of 41 patients. Cancer (1988) 0.81
Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes Chromosomes Cancer (1991) 0.81
Karyotypic stability in chronic B-cell leukemia. Cancer Genet Cytogenet (1988) 0.80
Chromosomal aberrations in progressive and indolent chronic B-lymphocytic leukaemia. A longitudinal study. Acta Oncol (1988) 0.78
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum (2006) 5.03
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet (2007) 3.00
Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood (2002) 3.00
Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates. Blood (2010) 2.98
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2005) 2.92
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2009) 2.68
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol (2008) 2.67
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics (2008) 2.66
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
A comparison of infraclavicular nerve block versus general anesthesia for hand and wrist day-case surgeries. Anesthesiology (2004) 2.43
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med (2005) 2.36
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood (2010) 2.33
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum (2003) 2.17
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012) 2.14
Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40. J Natl Cancer Inst (2003) 2.07
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood (2007) 2.02
Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer (2008) 2.02
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
Characterization of the RNA content of chromatin. Genome Res (2010) 1.99
Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet (2002) 1.97
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood (2008) 1.93
Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst (2007) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Familial risk of multiple sclerosis: a nationwide cohort study. Am J Epidemiol (2005) 1.84
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood (2004) 1.77
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 1.74
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood (2011) 1.74
Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood (2009) 1.69
Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst (2006) 1.68
Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation. Development (2008) 1.68
CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. Eur J Haematol (2006) 1.66
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer (2008) 1.66
Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma (2013) 1.64
Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol (2008) 1.63
Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin Cytom (2007) 1.61
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol (2010) 1.57
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination. Leuk Lymphoma (2008) 1.54
Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol (2010) 1.54
Duration of red blood cell storage and survival of transfused patients (CME). Transfusion (2010) 1.53
Male microchimerism and survival among women. Int J Epidemiol (2013) 1.53
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma (2008) 1.53
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood (2011) 1.49
Parallel gene analysis with allele-specific padlock probes and tag microarrays. Nucleic Acids Res (2003) 1.48
Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily. Leuk Lymphoma (2011) 1.47
Epidemiology of Massive Transfusion: A Binational Study From Sweden and Denmark. Crit Care Med (2016) 1.47
Early parental death and risk of hospitalization for affective disorder in adulthood. Epidemiology (2013) 1.46
Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol (2004) 1.46
Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res (2007) 1.45
Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol (2011) 1.45
Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res (2009) 1.45
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res (2009) 1.43